Key result
Targeted cancer therapies, particularly TKIs, can cause unanticipated left ventricular dysfunction and heart failure.
Why the study?
Targeted cancer therapies inhibiting tyrosine kinase activity have improved cancer management but have revealed unanticipated cardiotoxic side effects including left ventricular dysfunction and heart failure.
Do tyrosine kinase inhibitors cause left ventricular dysfunction and heart failure in patients with cancer?
Population
Patients with cancer treated with targeted therapeutics
Design
Review
Authors
Loading...
Understanding the molecular mechanisms of TKI-induced cardiotoxicity is crucial for managing cancer patients on these potentially life-saving therapies.
Do tyrosine kinase inhibitors cause left ventricular dysfunction and heart failure in patients with cancer?
Understanding the molecular mechanisms of TKI-induced cardiotoxicity is crucial for managing cancer patients on these potentially life-saving therapies.
Chen et al. (2008) conducted a review in Cancer. Tyrosine kinase inhibitors and monoclonal antibodies was evaluated. Targeted cancer therapies, particularly tyrosine kinase inhibitors, can cause unanticipated cardiotoxicity including left ventricular dysfunction and heart failure through on-target and off-target mechanisms.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: